menu
    • menu
    [{"orgOrder":0,"company":"Amarna Therapeutics","sponsor":"Amarna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SPAIN","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"SV40 vector based gene therapy","moa":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"Amarna Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Amarna Therapeutics \/ Amarna Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Amarna Therapeutics \/ Amarna Therapeutics"},{"orgOrder":0,"company":"Amarna Therapeutics","sponsor":"C4 holding BV","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2021","type":"Financing","leadProduct":"AMA005","moa":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Amarna Therapeutics","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Amarna Therapeutics \/ C4 holding BV","highestDevelopmentStatusID":"5","companyTruncated":"Amarna Therapeutics \/ C4 holding BV"},{"orgOrder":0,"company":"Amarna Therapeutics","sponsor":"NorthX Biologics","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Partnership","leadProduct":"Nimvec AM510","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Amarna Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"Amarna Therapeutics \/ NorthX Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Amarna Therapeutics \/ NorthX Biologics"},{"orgOrder":0,"company":"Amarna Therapeutics","sponsor":"Eurostars","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":null,"graph2":null,"graph3":"Amarna Therapeutics","amount2":0,"highestDevelopmentShortName":null,"therapeuticAreaShortName":null,"amount2New":0,"dosageForm":"","sponsorNew":"Amarna Therapeutics \/ Eurostars","highestDevelopmentStatusID":null,"companyTruncated":"Amarna Therapeutics \/ Eurostars"}]

    Find Clinical Drug Pipeline Developments & Deals by Amarna Therapeutics

    Menu

    Amarna Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Amarna Therapeutics

                            Netherlands arrow
                            PharmaVenue
                            Not Confirmed

                            Amarna Therapeutics

                            Netherlands arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Ophthalmology

                            Study Phase : Discovery Platform

                            Sponsor : Eurostars

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Phenocell, Amarna Win Grant To Study Gene Therapy for Dry AMD Using Retinal Model

                            Details : Eurostars' funding will support their collaboration to validate Amarna's patented gene therapy platform using a novel and advanced cellular disease model for Dry AMD.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            December 11, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Discovery Platform

                            Sponsor : Eurostars

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Amarna Therapeutics

                            Netherlands arrow
                            PharmaVenue
                            Not Confirmed

                            Amarna Therapeutics

                            Netherlands arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nimvec AM510

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Sponsor : NorthX Biologics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Amarna Partners with NorthX to Advance Nimvec™ AM510 Gene Therapy Program

                            Details : The partnership focuses on advancing the clinical trial manufacturing of Nimvec AM510, Amarna’s groundbreaking gene therapy platform designed to transform the treatment of type 1 diabetes.

                            Brand Name : Nimvec AM510

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            December 03, 2024

                            Lead Product(s) : Nimvec AM510

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Sponsor : NorthX Biologics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Amarna Therapeutics

                            Netherlands arrow
                            PharmaVenue
                            Not Confirmed

                            Amarna Therapeutics

                            Netherlands arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AMA005

                            Therapeutic Area : Genetic Disease

                            Study Phase : IND Enabling

                            Sponsor : C4 holding BV

                            Deal Size : $5.7 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Amarna Therapeutics Secures Additional €5 ($5.7) Million to Advance Its Transformative Gene Therapy Platform...

                            Details : The funds will enable Amarna to advance its lead gene therapy AMA005, for the treatment of hemophilia B towards a first-in-human clinical trial, and to progress its R&D pipeline in selected autoimmune diseases and chronic inflammation.

                            Brand Name : AMA005

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            December 01, 2021

                            Lead Product(s) : AMA005

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : IND Enabling

                            Sponsor : C4 holding BV

                            Deal Size : $5.7 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Amarna Therapeutics

                            Netherlands arrow
                            PharmaVenue
                            Not Confirmed

                            Amarna Therapeutics

                            Netherlands arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SV40 vector based gene therapy

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Recipient : Progreso y Salud Foundation

                            Deal Size : $0.7 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Amarna Announces Research Join Hands with Progreso y Salud Foundation for Testing MS Gene Therapy Platform

                            Details : The collaboration is a joint effort between the research group of the FPS at research institute Cabime and Amarna Therapeutics which aims to assess the efficacy of SVec in reducing the immune responses that trigger the damage and loss of myelin in animal...

                            Brand Name : SVec

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            September 25, 2020

                            Lead Product(s) : SV40 vector based gene therapy

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Recipient : Progreso y Salud Foundation

                            Deal Size : $0.7 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth